New drug combo aims to keep High-Risk nasopharyngeal cancer at bay
NCT ID NCT06277050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding toripalimab (an immunotherapy) to capecitabine (a chemotherapy pill) as maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. The study enrolls 264 adults aged 18-70 who have completed initial chemotherapy and radiation. The goal is to see if the combination delays cancer progression or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital
RECRUITINGNanchang, None Selected, 330029, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
First Affiliated hospital of Gannan Medical University
RECRUITINGGuangzhou, Jiangxi, 341000, China
Contact
Contact
Contact
-
Ganzhou Cancer Hospital
NOT_YET_RECRUITINGGanzhou, Jiangxi, 341000, China
Contact
Contact
Contact